Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Timeline
  • Published:

The life and times of ivermectin — a success story

Nature Reviews Microbiology volume 2, pages 984–989 (2004)Cite this article

Abstract

Since its introduction more than 20 years ago, ivermectin has proved to be one of the most successful therapeutic drugs in veterinary medicine, as well as the basis of one of the most successful public-health programmes of the past century. The drug arose from a unique international collaboration between the public and private sectors. The development process also incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry. The drug is now being used, free of charge, in two global disease-elimination programmes that are benefiting millions of the world's poorest people.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Micrograph of Streptomyces avermectinius.
Figure 2: Structure of the avermectins.
Figure 3: Schematic representation of the life cycle of Onchocerca volvulus.
Figure 4: Global distribution of onchocerciasis.

References

  1. Õmura, S. Philosophy of new drug discovery. Microbiol. Rev. 50, 259–279 (1986).

    PubMed  PubMed Central  Google Scholar 

  2. Campbell, W. C. in Inventive Minds (eds Weber, R. J. & Perkins, D. N.) Chapter 11, 192–214 (Oxford Univ. Press, New York, 1992).

    Google Scholar 

  3. Burg, R. W. & Stapley, E. O. in Ivermectin and Abamectin (ed. Campbell, W. C.) 24–32 (Springer, New York, 1989).

    Book  Google Scholar 

  4. Takahashi, Y. et al. Streptomyces avermectinius sp. nov., an avermectin-producing strain. Int. J. Syst. Evol. Microbiol. 52, 2163–2168 (2002).

    CAS  PubMed  Google Scholar 

  5. Burg, R. W. et al. Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation. Antimicrob. Agents Chemother. 15, 361–367 (1979).

    Article  CAS  Google Scholar 

  6. Miller, T. W. Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob. Agents Chemother. 15, 368–371 (1979).

    Article  CAS  Google Scholar 

  7. Egerton, J. R. et al. Avermectins, new family of potent anthelmintic agents: efficacy of the B1A component. Antimicrob. Agents Chemother. 15, 372–378 (1979).

    Article  CAS  Google Scholar 

  8. Sunazuka, T. et al. in Macrolide Antibiotics — Chemistry, Biology and Practice 2nd ed. (ed. S. Õmura) 99–180 (Academic Press, 2002).

    Google Scholar 

  9. Chabala, J. C. et al. Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23, 1134–1136 (1980).

    Article  CAS  Google Scholar 

  10. Taylor, H. R. & Greene, B. M. The status of ivermectin in the treatment of human onchocerciasis. Am. J. Trop. Med. Hyg. 41, 460–466 (1989).

    Article  CAS  Google Scholar 

  11. Õmura, S. et al. Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc. Natl Acad. Sci. USA 98, 12215–12220 (2001).

    Article  Google Scholar 

  12. Ikeda, H. et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nature Biotechnol. 21, 526–531 (2003).

    Article  Google Scholar 

  13. Õmura, S. in Macrolide Antibiotics — Chemistry, Biology and Practice 2nd edn (ed. Omura, S.) 571–576 (Academic Press, 2002).

    Google Scholar 

  14. Duce, R. & Scott, R. H. Actions of dihydroavermectin B1a on insect muscle. Br. J. Pharmacol. 85, 395–401 (1985).

    Article  CAS  Google Scholar 

  15. Geary, T. G. et al. Haemonchus contortus: ivermectin-induced paralysis of the pharynx. Exp. Parasitol. 77, 88–96 (1993).

    Article  CAS  Google Scholar 

  16. Fritz, L. C. et al. Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc. Natl Acad. Sci. USA 76, 2062–2066 (1979).

    Article  CAS  Google Scholar 

  17. Mellin, T. N. et al. Postsynaptic inhibition of invertebrate neuromuscular transmission by avermectin B1a . Neuropharmacology 22, 89–96 (1983).

    Article  CAS  Google Scholar 

  18. Turner, M. & Schaeffer J. M. in Ivermectin and Abamectinn (ed. Campbell, W. C.) 73–88 (Springer, New York, 1989).

    Book  Google Scholar 

  19. TDR. Twelfth Programme Report. Tropical Disease Research: progress 1975–94, highlights 1993–94. (WHO, Geneva, 1995).

  20. Thylefors, B. Eliminating onchocerciasis as a public health problem. Trop. Med. Int. Health 9, A1–A3 (2004).

    Article  CAS  Google Scholar 

  21. Aziz, M. A. et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 2, 171–173 (1982).

    Article  CAS  Google Scholar 

  22. Aziz, M. A. et al. Ivermectin in onchocerciasis. Lancet 2, 1456–1457 (1982).

    Article  CAS  Google Scholar 

  23. White, A. T. et al. Controlled trial and dose-finding study of ivermectin for treatment of infectious diseases. J. Infect. Dis. 156, 463–470 (1987).

    Article  CAS  Google Scholar 

  24. Greene, B. M. et al. Single dose therapy with ivermectin for onchocerciasis. Trans. Assoc. Am. Physicians 100, 131–138 (1987).

    CAS  PubMed  Google Scholar 

  25. Newland, H. S. et al. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement. Br. J. Opthalmol. 72, 561–569 (1988).

    Article  CAS  Google Scholar 

  26. Remme, J. H. F. et al. Large-scale ivermectin distribution and its epidemiological consequences. Acta Leiden. 59, 177–191 (1990).

    CAS  PubMed  Google Scholar 

  27. Duke, B. O. L. et al. Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus. Am. J. Trop. Med. Hyg. 43, 657–664 (1990).

    Article  CAS  Google Scholar 

  28. Campbell, W. C. et al. Ivermectin: a potent new antiparasitic agent. Science 221, 823–828 (1983).

    Article  CAS  Google Scholar 

  29. Whitworth, J. A. G. et al. Clinical and parasitological response after up to 6.5 years of ivermectin treatment for onchocerciasis. Trop. Med. Int. Health 1, 786–793 (1992).

    Article  Google Scholar 

  30. Alley, E. S. et al. The impact of five years of annual ivermectin treatment on microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans. R. Soc. Trop. Med. Hyg. 88, 581–584 (1994).

    Article  CAS  Google Scholar 

  31. Kennedy, M. H. et al. The effect of five years of annual treatment with ivermectin (Mectizan®) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann. Trop. Med. Parasitol. 49, 804–811 (2002).

    Google Scholar 

  32. Whitworth, J. A. G. et al. A community trial of ivermectin for onchocerciasis in Sierra Leone; clinical and parasitological response to four doses given at six-monthly intervals. Trans. R. Soc. Trop. Med. Hyg. 86, 277–280 (1996).

    Article  Google Scholar 

  33. Duke, B. O. L. et al. Effects of three-month doses of ivermectin on adult Onchocerca volvulus. Am. J. Trop. Med. Hyg. 46, 189–194 (1992).

    Article  CAS  Google Scholar 

  34. Taylor, H. R. et al. Comparison of the treatment of ocular onchocerciaisis with ivermectin and diethylcarbamazine. Arch. Opthalmol. 104, 863–870 (1986).

    Article  CAS  Google Scholar 

  35. Pacqué, M. et al. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy and acceptability of yearly treatment. J. Infect. Dis. 163, 381–385 (1991).

    Article  Google Scholar 

  36. Chijioke, C. P. & Okonkwo, P. Adverse events following mass ivermectin therapy for onchocerciasis. Trans. R. Soc. Trop. Med. Hyg. 86, 284–286 (1992).

    Article  CAS  Google Scholar 

  37. De Sole, G. et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull. World Health Organ. 67, 707–719 (1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Gardon, J. et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350, 18–22 (1997).

    Article  CAS  Google Scholar 

  39. Twum-Danso, N. A. Y. Serious adverse events following treatment with ivermectin for onchocerciais control: a review of reported cases. Filaria J. 2 (Suppl.), S3–S13 (2003).

    Article  Google Scholar 

  40. WHO. Strategies for ivermectin distribution through primary health care systems. WHO/PBL/91. 24. (WHO, Geneva, 1991).

  41. Mectizan Donation Programme. Newsletter of the Mectizan Donation Programme. [online], <http://www.mectizan.org/mpn33/mpnhtml336.htm> (2004).

  42. Waters, H. R. et al. Economic evaluation of Mectizan distribution. Trop. Med. Int. Health 9, A16–A25 (2004).

    Article  CAS  Google Scholar 

  43. Burnham, G. & Mebrahtu, T. The delivery of ivermectin (Mectizan). Trop. Med. Int. Health 9, A26–A44 (2004).

    Article  CAS  Google Scholar 

  44. Onwujekwe, O. et al. Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis endemic communities in Nigeria. Trop. Med. Int. Health 3, 802–808 (1998).

    Article  CAS  Google Scholar 

  45. Onwujekwe, O. et al. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy 62, 31–51 (2002).

    Article  Google Scholar 

  46. Addis, D. G. et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 350, 480–484 (1997).

    Article  Google Scholar 

  47. Njoo, FL. et al. Concurrent parastic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment. Am. J. Trop. Med. Hyg. 48, 652–657 (1993).

    Article  CAS  Google Scholar 

  48. Stephenson, L. S. Optimising the benefits of anthelmintic treatment in children. Paediatr. Drugs 3, 495–508 (2001).

    Article  CAS  Google Scholar 

  49. Dunne, C. L. et al. A field study of the effects of ivermectin on ectoparasites of man. Trans. R. Soc. Trop. Med. Hyg. 85, 550–551 (1991).

    Article  CAS  Google Scholar 

  50. Blackhall, W. J. et al. Selection at a P-glycoprotein gene in ivermectin and moxidectin-selected strains of Haemonchus contortus. Mol. Biochem. Parasitol. 95, 193–201 (1998).

    Article  CAS  Google Scholar 

  51. Kwa, M. S. et al. Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus. Int. J. Parasitol. 28, 1235–1240 (1998).

    Article  CAS  Google Scholar 

  52. Eckholm, E. Conquering an ancient scourge; river blindness. New York Times Magazine, 20–27 (Jan 8, 1989).

  53. Ikeda, H. & Õmura, S. in Macrolide Antibiotics (ed. Õmura, S.) 287–326 (Academic Press, San Diego, 2002).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8642, Japan

    Satoshi Õmura

  2. 6-2-4-403 Shinjuku, Shinjuku-ku, Tokyo, 160-0022, Japan

    Andy Crump

Authors
  1. Satoshi Õmura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andy Crump
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Õmura.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

WHO

TDR

Onchocerciasis control programme

African programme for onchocerciasis control

Global alliance to eliminate lympatic filariasis

CDC onchocerciasis fact sheet

CDC lymphatic filariasis fact sheet

Rights and permissions

Reprints and permissions

About this article

Cite this article

Õmura, S., Crump, A. The life and times of ivermectin — a success story. Nat Rev Microbiol 2, 984–989 (2004). https://doi.org/10.1038/nrmicro1048

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrmicro1048

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing